Internal Medicine, Infectious Disease · Neptune, NJ
NPI
1669441465
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
19 Davis Ave Fl 6
Neptune, NJ, 07753
Phone (732) 897-3995
Groups this clinician bills Medicare through
Medicare paid, 2024
$38K
332 services
Medicare patients, 2024
252
Average age 76
Drug cost, 2024
$815K
603 prescriptions
Company payments, 2025
$251
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nancy J Kruvant-Gornish was code 99223 (hospital e&m - initial), 180 times for 172 patients. In total Nancy J Kruvant-Gornish billed 332 services in 17 codes, and Medicare paid $38K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-01-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99223 Hospital E&M - Initial | Facility | 180 | 172 | $138.67 | $25K |
| 99213 Office E&M - Established | Office | 42 | 23 | $72.88 | $3,061 |
| 99214 Office E&M - Established | Office | 25 | 17 | $89.86 | $2,246 |
| 99233 Hospital E&M - Subsequent | Facility | 22 | 21 | $99.93 | $2,198 |
| 99204 Office E&M - New | Office | 15 | 15 | $144.15 | $2,162 |
| 99203 Office E&M - New | Office | 13 | 13 | $96.00 | $1,248 |
By year: 2022 $94K for 1,128 services; 2023 $64K for 731 services; 2024 $38K for 332 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nancy J Kruvant-Gornish prescribed most often to Medicare patients was Tivicay (Dolutegravir Sodium), with 54 prescriptions and refills. In total Nancy J Kruvant-Gornish wrote 603 Medicare prescriptions that cost $815K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tivicay Dolutegravir Sodium | 54 | 58 | Under 11 | $131K |
| Descovy Emtricitabine/Tenofov Alafenam | 37 | 37 | Under 11 | $82K |
| Prezcobix Darunavir/Cobicistat | 35 | 35 | Under 11 | $85K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 32 | 32 | Under 11 | $128K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 21 | 28 | Under 11 | $64.45 |
| Gabapentin Generic | 20 | 33 | Under 11 | $196 |
| Dovato Dolutegravir Sodium/Lamivudine | 17 | 23 | Under 11 | $64K |
| Valacyclovir Valacyclovir Hcl | 14 | 20 | Under 11 | $390 |
| Levetiracetam Generic | 13 | 13 | Under 11 | $137 |
| Etravirine Generic | 13 | 17 | Under 11 | $16K |
| Zidovudine Generic | 13 | 25 | Under 11 | $948 |
| Darunavir Generic | 13 | 17 | Under 11 | $22K |
| Ritonavir Generic | 13 | 17 | Under 11 | $1,215 |
| Complera Emtricita/Rilpivirine/Tenof Df | 12 | 12 | Under 11 | $43K |
| Epinephrine Generic | 12 | 12 | Under 11 | $2,475 |
Brand drugs: - claims; generic drugs: 345 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nancy J Kruvant-Gornish $251 ($251 in general payments such as food, travel and fees) from 8 companies. The largest payer was ViiV Healthcare Company with $55.92.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.